Publications by authors named "Chenchang Li"

Claim this Profile
E
Elevated Eosinophil Counts in Acute Exacerbations of Bronchiectasis: Unveiling a Distinct Clinical Phenotype.
Weixin Chen, Siyi Ran, Chenchang Li, Zhixin Li, Nili Wei, Jing Li, Naijian Li

Lung· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating Latent Interactions between Students' Affective Cognition and Learning Performance: Meta-Analysis of Affective and Cognitive Factors.
Jian Li, Eryong Xue, Chenchang Li, Yunshu He

Behav Sci (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist.
Xishan Wu, Hui Shen, Yan Zhang, Chao Wang, Qiu Li, Chenchang Li, Yanli Xing, Jinsong Liu

J Med Chem· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Ling-Jiao Zou, Qiu-Ping Xiang, Xiao-Qian Xue, Cheng Zhang, Chen-Chang Li, Qiu Li

Acta Pharmacol Sin· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
Yan Zhang, Xishan Wu, Xiaoqian Xue, Chenchang Li, Junjian Wang, Lingjiao Zou, Qiu Li

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
Xiaoqian Xue, Yan Zhang, Chao Wang, Maofeng Zhang, Qiuping Xiang, Chenchang Li, Lingjiao Zou, Guohui Li

Eur J Med Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
Maofeng Zhang, Yan Zhang, Ming Song, Xiaoqian Xue, Junjian Wang, Chenchang Li, Lingjiao Zou

J Med Chem· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Qiuping Xiang, Chao Wang, Yan Zhang, Xiaoqian Xue, Ming Song, Chenchang Li, Kuai Li

Eur J Med Chem· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.
Qiuping Xiang, Yan Zhang, Jiaguo Li, Xiaoqian Xue, Chao Wang, Chenchang Li, Guohui Li

ACS Med Chem Lett· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis